StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Constant Currency Growth in Rest of World (% cc) by Quarter

Constant Currency Growth in Rest of World (% cc) (%)

QuarterlyAnnual

Novartis Constant Currency Growth in Rest of World (% cc): 14.0% in Q3 2026, up 19.0 pts from a year earlier.

Latest, Q3 2026
14.0%
Period ended Sep 30, 2026
Change on a year earlier
+19.0 pts
-5.0% in Q3 2025
History
22 quarters
Since Q2 2021
Sources
22
Documents cited below

Where the Q3 2026 figure comes from

“|| Zolgensma Group | Neuroscience | Spinal muscular atrophy (SMA) | 173 | 78 | 231 | 13 | 14 | 404 | 34 | 35”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedConstant Currency Growth in Rest of World (% cc) (%)Year on yearSource
Q3 2026Sep 30, 202614.0%+19.0 ptsNovartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 20262.0%+12.0 ptsNovartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 2026-14.0%-21.0 ptsNovartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 202522.0%+34.0 ptsNovartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 2025-5.0%0.0 ptsNovartis Form 6-K (0001114448-25-000003) ↗
Q2 2025Jun 30, 2025-10.0%-7.0 ptsNovartis Form 6-K (0001370368-25-000012) ↗
Q1 2025Mar 31, 20257.0%+9.0 ptsNovartis Form 6-K (0001370368-25-000010) ↗
Q4 2024Dec 31, 2024-12.0%-11.0 ptsNovartis Form 6-K (0001370368-25-000007) ↗
Q3 2024Sep 30, 2024-5.0%-7.0 ptsNovartis Form 6-K (0001370368-24-000022) ↗
Q2 2024Jun 30, 2024-3.0%+6.0 ptsNovartis Form 6-K (0001370368-24-000019) ↗
Q1 2024Mar 31, 2024-2.0%+17.0 ptsNovartis Form 6-K (0001370368-24-000017) ↗
Q4 2023Dec 31, 2023-1.0%-1.0 ptsNovartis Form 6-K (0001370368-24-000007) ↗
Q3 2023Sep 30, 20232.0%+10.0 ptsNovartis Form 6-K (0001370368-23-000068) ↗
Q2 2023Jun 30, 2023-9.0%-40.0 ptsNovartis Form 6-K (0001370368-23-000059) ↗
Q1 2023Mar 31, 2023-19.0%-51.0 ptsNovartis Form 6-K (0001370368-23-000046) ↗
Q4 2022Dec 31, 20220.0%-58.0 ptsNovartis Form 6-K (0001370368-23-000008) ↗

Cite this data

StockData. (2026). Novartis Constant Currency Growth in Rest of World (% cc) (%), quarterly Q2 2021–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-zolgensma-group-row-yoy-cc-pct

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.